Agrivida

Market position

Agrivida described GRAINZYME as the first corn-based enzyme platform available to animal nutritionists and feed formulators, positioned against conventional fermentation-produced feed enzymes. It reported commercial use in over 50 million chickens by December 2019 and was characterized by its acquirer as a start-up whose bandwidth to develop and commercialize products was limited by its resources and lack of global reach prior to the acquisition [0][3][7].

Enzymes are produced within the corn kernel rather than by fermentation, removing separate manufacturing, coating and blending steps, enabling delivery of a customized enzyme payload with the grain itself, providing nutrient credits that conserve ration space, and, per the acquirer, allowing more efficient absorption and the potential to stack multiple functional proteins in a single ingredient [0][1][3][7].

Technology

The core technology, later branded INTERIUS, engineers corn plants to express enzymes and other functional proteins directly inside the kernel rather than producing them by microbial fermentation. High enzyme concentration allows 2 to 4 pounds of ground GRAINZYME corn per ton of feed to deliver super-dosed phytase levels, while the corn itself provides nutrient credits within the ration. The platform is described as extensible to customized enzyme payloads such as glucanase and, under Novus, to single-domain antibodies and stacked enzyme/antibody combinations in one corn ingredient [0][1][3][7].

Go-to-market

Agrivida marketed directly to commercial poultry and swine operations, running commercial trials with producers and pursuing strategic collaborations, and supplied ground GRAINZYME corn to feed mills. From December 2020 it used a commercial partnership with Novus International to support sales of GRAINZYME. It also publicly solicited strategic partners and investors via its website [0][1][3][4][7].

Livestock producers, feed mills, animal nutritionists and feed formulators, initially in poultry and swine, with stated expansion targets in dairy and beef cattle and aquaculture; the company also sought swine producers to run commercial trials [0][1][2][3][4].

Geography

Operations in Massachusetts and Nebraska at the time of the 2023 acquisition; press releases in 2019 and 2021 were issued from Woburn, Massachusetts, and a January 2022 release from Boston, Massachusetts. A 2019 investor release listed headquarters in Village of Four Seasons, Missouri. USDA deregulation permits GRAINZYME Phytase corn to be grown anywhere in the United States, and the company stated global market ambitions in poultry and swine [3][4][7].

History

After its 2003 founding, Agrivida worked on projects ranging from improving biofuel production to addressing enzyme use in consumer products, earning research grants from the U.S. Department of Agriculture and the U.S. Department of Energy. It later concentrated on feed enzymes, obtaining FDA Center for Veterinary Medicine approval for GRAINZYME Phytase sale into US swine on July 8, 2019, and announcing swine availability in December 2019 following GRAS status. In July 2019 it launched a $20 million financing round led by the Open Prairie Rural Opportunities Fund. A commercial partnership with Novus International began in December 2020; USDA APHIS deregulation of GRAINZYME Phytase took effect September 21, 2021; and Novus International acquired the company in January 2023 [2][3][4][6][7].

Risks & controversies

The product is a genetically engineered crop subject to regulatory review; Agrivida voluntarily sought USDA APHIS deregulation and completed an FDA Biotechnology Notification review of food and feed safety before its enzyme corn could be grown without restriction in the United States. Prior to acquisition, the company's CTO stated that its ability to develop and commercialize products was limited by its resources and global expertise [3][7].